Big Buttons

• FDA doubles down: Tirzepatide is off shortage

  ...but that doesn't mean the issue is completely settled. read more →

• A couple of state updates

  Good news from Alabama, but a problem in Massachusetts read more →

• Defending GLP-1 compounding

  The latest letters APC's been sending to oppose efforts to restrict compounding read more →

• Thumbs-up for FDA crackdown

  APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →

• A PANS/PANDAS explainer

  For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →

• What, a year?

  In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →

• “Simply not a rational approach to regulating an industry”

  This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →

• Get a cease and desist letter from Verrica?

  APC has heard reports from several pharmacies that have received them — here's what to know. read more →

More News

APC’s Board this week approved minor revisions to its policy statement on Constructive Transfer of compounded controlled substance drugs. The statement was first adopted in 2010.  The new revisions provide pharmacy compounders with an updated briefing, highlighting the DEA’s recent limited enforcement actions regarding the constructive transfer of controlled substances to physicians. The statement also reiterates the position the DEA has taken regarding pharmacists and their obligations outlined in the federal Controlled Substances Act. 

“The provided information aims to support pharmacists in making informed decisions regarding the delivery of controlled substances to prescribers for in-office administration, including certain dosage forms of ketamine,” said APC’s Tenille Davis.